Oracle Announces Release of Remote Data Capture 4.6
Oracle (Redwood Shores, CA) announced the release of Remote Data Capture 4.6. The company collaborated with customer advisors to develop additional functions for the EDC application. The latest additions include scalability improvements, flexible branching to support complex trial design (including for oncology trials), access restriction capabilities, and patient management enhancements.
Remote Data Capture is integrated with the company’s clinical data management system, Oracle Clinical.
“R&D efficiency, clinical effectiveness and time to market continue to be the greatest challenges facing life sciences organizations today,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences, in a company press release. “Oracle Remote Data Capture 4.6 provides strong evidence of our unwavering commitment to helping clinical trial sponsors and CROs accelerate insights for better health, and will enable our customers to complete clinical trials significantly faster and much more cost effectively than ever before.”
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
